# Gain Therapeutics, Inc. (GANX)

> Source: Nexqual · https://nexqual.com/GANX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Gain Therapeutics, Inc. (GANX), nexqual.com/GANX" · informational, not investment advice.

**Price:** USD 1.33 (+0.76% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.32 · day 1.31–1.41 · 52w 1.3–4.34 · market cap $58.0M · NGM

## Key facts
- 1 of 80 tracked superinvestors hold GANX (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 7.2 (range 5–8).
- Total return with dividends: 1Y -26.5% vs S&P 500 +18.1%; 5Y -80.8% vs S&P 500 +85.1%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $165K | $140K | $55K | — | — | — |
| Operating income | -$13.8M | -$17.8M | -$22.3M | -$20.4M | -$18.7M | -$19.3M |
| Net income | -$13.9M | -$17.6M | -$22.3M | -$20.4M | -$20.2M | -$20.1M |
| EPS (diluted) | -$1.37 | -$1.48 | -$1.71 | -$0.89 | -$0.61 | — |
| Free cash flow | -$12.5M | -$14.8M | -$18.9M | -$18.9M | — | — |
| Operating margin | -8379.8% | -12688.1% | -40328.3% | — | — | — |
| Net margin | -8418.9% | -12555.1% | -40354.3% | — | — | — |
| Revenue growth | +471.3% | -15.1% | -60.6% | — | — | — |
| Cash + short-term investments | $36.9M | $20.1M | $16.8M | — | — | — |
| Total debt | $694K | $603K | $568K | $439K | $401K | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 5.1x · Earnings yield -34.64% · Net cash $12.7M · EV $45.3M

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold GANX. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| David Einhorn | Greenlight Capital | 0.03% | $1.1M | Unchanged |

## Analysts
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 7.2 (low 5, high 8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| 2026-08-31 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| 2026-08-11 | BTIG | Reiterated | Buy | $5 |
| 2026-07-01 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| 2026-06-30 | BTIG | Maintained | Buy | $5 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -26.5% | -80.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -26.6% | -28.1% |
| Volatility (annualized) | 111.3% | 82.8% |
| Max drawdown | -68.4% (Dec 2025→Oct 2026) | -88.1% (Nov 2021→Aug 2024) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/GANX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt